Literature DB >> 17697896

Design and chemical synthesis of integrin ligands.

Dominik Heckmann1, Horst Kessler.   

Abstract

The design and synthesis of peptidic and nonpeptidic integrin ligands derived from the most abundant natural tripeptide sequence, RGD, are described in this article. Special emphasis is placed on the activity and selectivity of the ligands to integrin subtypes. Two approaches are described-ligand- and structure-oriented design. When no structure of the complex or the target is known, one may derive suitable starting points from natural peptide sequences, which often require conformational restriction for a further optimization. A "spatial screening" procedure was used to identify highly active and selective ligands for the integrin subtypes alphavbeta3 and alphaIIbbeta3. Structure-based methods require knowledge of the binding domain of the target. Hence, the first structure of the alphavbeta3 integrin with bound cilengitide was a landmark for the structure-based approach. Meanwhile, a design using homology models of other integrin subtypes has also been successfully applied. To improve the ADME profile, nonpeptidic ligands have been developed using the information of the spatial distances and orientations of the most important pharmacophoric groups (especially the carboxyl group and the basic moiety at the other end of the molecule). Applications of the alphavbeta3 ligands as drugs in antiangiogenic tumor therapy for molecular imaging of metastases and for improvement of biocompatibility of grafts are briefly described.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17697896     DOI: 10.1016/S0076-6879(07)26020-3

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  21 in total

1.  Advantages of RGD peptides for directing cell association with biomaterials.

Authors:  Susan L Bellis
Journal:  Biomaterials       Date:  2011-06       Impact factor: 12.479

2.  Integrin targeted therapeutics.

Authors:  Melissa Millard; Srinivas Odde; Nouri Neamati
Journal:  Theranostics       Date:  2011-02-17       Impact factor: 11.556

3.  Exploring new near-infrared fluorescent disulfide-based cyclic RGD peptide analogs for potential integrin-targeted optical imaging.

Authors:  Yunpeng Ye; Baogang Xu; Gregory V Nikiforovich; Sharon Bloch; Samuel Achilefu
Journal:  Bioorg Med Chem Lett       Date:  2011-02-23       Impact factor: 2.823

4.  Responsive Hybrid (Poly)peptide-Polymer Conjugates.

Authors:  Bradford A Paik; Shivshankar R Mane; Xinqiao Jia; Kristi L Kiick
Journal:  J Mater Chem B       Date:  2017-10-06       Impact factor: 6.331

Review 5.  Conjugates of Cell Adhesion Peptides for Therapeutics and Diagnostics Against Cancer and Autoimmune Diseases.

Authors:  Mario E G Moral; Teruna J Siahaan
Journal:  Curr Top Med Chem       Date:  2017       Impact factor: 3.295

6.  Multiple N-methylation of MT-II backbone amide bonds leads to melanocortin receptor subtype hMC1R selectivity: pharmacological and conformational studies.

Authors:  Lucas Doedens; Florian Opperer; Minying Cai; Johannes G Beck; Matt Dedek; Erin Palmer; Victor J Hruby; Horst Kessler
Journal:  J Am Chem Soc       Date:  2010-06-16       Impact factor: 15.419

Review 7.  Virus-Derived Peptides for Clinical Applications.

Authors:  Mingying Yang; Kegan Sunderland; Chuanbin Mao
Journal:  Chem Rev       Date:  2017-07-19       Impact factor: 60.622

8.  Priming integrin alpha5 promotes human mesenchymal stromal cell osteoblast differentiation and osteogenesis.

Authors:  Zahia Hamidouche; Olivia Fromigué; Jochen Ringe; Thomas Häupl; Pascal Vaudin; Jean-Christophe Pagès; Samer Srouji; Erella Livne; Pierre J Marie
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-20       Impact factor: 11.205

9.  Cilengitide, a small molecule antagonist, targeted to integrin αν inhibits proliferation and induces apoptosis of laryngeal cancer cells in vitro.

Authors:  Jing Ting Wang; Ying Liu; Xuan Kan; Ming Liu; Jian Guang Lu
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-02-11       Impact factor: 2.503

10.  Structural and therapeutic insights from the species specificity and in vivo antithrombotic activity of a novel alphaIIb-specific alphaIIbbeta3 antagonist.

Authors:  Robert Blue; M Anna Kowalska; Jessica Hirsch; Marta Murcia; Christin A Janczak; Amanda Harrington; Marketa Jirouskova; Jihong Li; Rudy Fuentes; Michael A Thornton; Marta Filizola; Mortimer Poncz; Barry S Coller
Journal:  Blood       Date:  2009-05-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.